Drug intelligence / Profile preview

vinblastine + vincristine

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

Vinblastine and vincristine are vinca alkaloids isolated from the Madagascar periwinkle (Catharanthus roseus). Both drugs act as antimicrotubule agents that block mitosis by binding to tubulin, preventing microtubule assembly and inducing depolymerization of formed tubules. They are used in various chemotherapy regimens for different types of cancer.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on vinblastine + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vinblastine + vincristine.

Explore the full profile